Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Advanced Solid Tumors × cemiplimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 6 Carcinoma, Non-Small-Cell Lung 6 Neoplasms 5 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Prostatic Neoplasms 3 Carcinoma, Renal Cell 3 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Pancreatic Neoplasms 2 Head and Neck Neoplasms 2 Fallopian Tube Neoplasms 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Skin Neoplasms 1 Mycosis Fungoides 1 Multiple Myeloma 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma 1 Lung Neoplasms 1 Liposarcoma 1 Leiomyosarcoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Glioma 1 Glioblastoma 1 Diffuse Intrinsic Pontine Glioma 1 Cutaneous Squamous Cell Carcinoma 1

Interventions

Bevacizumab 5 Irinotecan 4 Injections 4 Paclitaxel 3 Leucovorin 3 Fluorouracil 3 Docetaxel 3 Capecitabine 3 trifluridine tipiracil drug combination 2 toripalimab 2 tislelizumab 2 pembrolizumab 2 Pemetrexed 2 Oxaliplatin 2 Fulvestrant 2 Carboplatin 2 BMS-753493 2 130-nm albumin-bound paclitaxel 2 palbociclib 1 mogamulizumab 1 lenvatinib 1 fluzoparib 1 fludarabine 1 cemiplimab 1 Sirolimus 1 Nivolumab 1 N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 1 N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1 HMPL-013 1 Gemcitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04626635 2026-02-02

COMBINE-EGFR-1

Regeneron Pharmaceuticals

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡